Zydus’ biopharma arm acquires global proprietary rights for Progeria treatment - Qoneqt
seach-icon
  • user-img

    Ansari Uzair in India

    04 May 06:00 PM


    thumbnail

    Zydus’ biopharma arm acquires global proprietary rights for Progeria treatment

    Sentynl, under Zydus Lifesciences, acquired global rights for Zokinvy, the first FDA-approved Progeria treatment. An acquisition milestone in expanding the rare disease medicines portfolio, focusing on supporting patients.